Resources Repository
-
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Europe | Policy/Regulation | Value of Information | State-Transition | Benefit-Cost Analysis | Infectious Diseases | Economics/Finance | North America -
ArticlePublication 2018DALYS and QALYs – Does the Choice of Measure Matter?
This article discusses the measurement of health benefits as a key issue in health economic …
This article discusses the measurement of health benefits as a key issue in health economic evaluations. Authors adapted two previously published models, a Markov model for human papilloma virus (HPV) vaccination, and a pneumococcal vaccination deterministic model (PNEUMO) that reported outputs in QALYs to estimate DALYs in 3 settings, Argentina, Chile, and the United Kingdom. While the authors found that QALY gains were larger than DALYs avoided in all countries for HPV, differences using QALYs…
Europe | Policy/Regulation | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | Latin America & Caribbean -
BookPublication 2016Cost-Effectiveness in Health and Medicine, 2nd Edition
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The …
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The Second Panel on Cost-Effectiveness in Health and Medicine included experts drawn from academia, healthcare administration, and government. The book offers advice for conducting analyses to improve the allocation of health resources, and is intended for economists, policy analysts, hospital executives, and students across health, business, and humanities disciplines. New components of this edition, include an in-depth review of the past 20…
Europe | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Economics/Finance | Health/Medicine | Global | North America -
ArticlePublication 2016Cost-Effectiveness of Collaborative Care for Depression and Comorbid Diabetes or CVD
This article, published in BMJ Open, presents an economic model that combines a decision tree …
This article, published in BMJ Open, presents an economic model that combines a decision tree and a Markov cohort model to investigate the long-term cost-effectiveness of collaborative care versus usual care for individuals with depression and comorbid diabetes and/or cardiovascular disease. Data from the COINCIDE trial informs the model input parameters. The COINCIDE trial is a randomized controlled trial of collaborative care versus usual care that enrolled 387 participants from 36 primary care general practices…
Europe | Mental Health | State-Transition | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2016Accounting for Technical, Ethical, and Political Factors in Priority Setting
This article investigates two cases of priority setting to explore how, in addition to technical …
This article investigates two cases of priority setting to explore how, in addition to technical considerations, ethical and political factors shape the allocation of health resources. First, they discuss how Thai authorities adjudicated a coverage decision for HLA-B*1502 screening, which meets the national cost-effectiveness threshold for only some of the conditions it can detect. Second, they consider England’s Cancer Drugs Fund to investigate the interplay of technical decision making and political reality. The findings suggest four concluding…
Europe | Policy/Regulation | Priority Setting/Ethics | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Climate/Environment | Government/Law | Health/Medicine | Science/Technology | Global -
BookPublication 2013Making Hard Decisions with Decision Tools, 3rd Edition
Making Hard Decisions with Decision Tools® is a new edition and teaches the fundamental ideas …
Making Hard Decisions with Decision Tools® is a new edition and teaches the fundamental ideas of decision analysis, without an overly technical explanation of the mathematics used in decision analysis. This new version has been purposefully written to be more relevant to students in business and engineering compared to previous versions. This new version also incorporates and implements the powerful DecisionTools® software by Palisade Corporation. At the end of each chapter, topics are illustrated with step-by-step instructions…
Europe | Policy/Regulation | Probability/Bayes | Preferences/Values | Test Performance | Value of Information | Microsimulation | Decision Analysis | Business/Industry | Energy/Engineering | Health/Medicine | Military/Defense | Science/Technology | Global | North America -
ArticlePublication 2011Cost-Effectiveness of Psychotherapy for Cluster C Personality Disorders
This article, published in the Journal of Clinical Psychiatry, describes a probabilistic Markov cohort model …
This article, published in the Journal of Clinical Psychiatry, describes a probabilistic Markov cohort model that compares the cost-effectiveness of five treatment modalities (long-term outpatient psychotherapy, short-term and long-term day hospital psychotherapy, and short-term and long-term inpatient psychotherapy) for patients with cluster C personality disorders. The analyses are conducted from the societal and payer perspectives. Patient-level data comes from 466 patients with cluster C personality disorders who were admitted to 6 specialist centers of psychotherapy…
Europe | Mental Health | State-Transition | Cost-Effectiveness Analysis | Health/Medicine -
ArticlePublication 2010Cost-Effectiveness of Psychotherapy for Cluster B Personality Disorders
This article, published in the British Journal of Psychiatry, presents a probabilistic Markov cohort model …
This article, published in the British Journal of Psychiatry, presents a probabilistic Markov cohort model that compares the cost-effectiveness of three treatment strategies (outpatient, day-hospital and inpatient psychotherapy) for patients with cluster B personality disorders. Patient-level data is used to populate the model and the analyses are conducted from the societal and payer perspectives. From the societal perspective, the findings show that the incremental cost-effectiveness ratio (ICER) of day hospital psychotherapy compared to outpatient psychotherapy…
Europe | Mental Health | State-Transition | Cost-Effectiveness Analysis | Health/Medicine -
ArticlePublication 2008Burden of Disease in Personality Disorders
The burden of disease in patients with personality disorders was investigated using a generic quality …
The burden of disease in patients with personality disorders was investigated using a generic quality of life measure. In a sample of 1,708 individuals with a clinical diagnoses of personality disorders the EuroQol EQ-5D (EQ-5D) was administered. The results showed that the mean EQ-5D score was 0.56 and that the total number of personality disorder diagnoses rather than the specific type of disorder determined the quality of life. The borderline personality disorder was not associated…
Europe | Mental Health | Health Outcomes | Health/Medicine